These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6222235)

  • 21. [Modern prospects in the treatment of cancer of the breast and its metastasis. Medroxyprogesterone in massive doses as an alternative to polychemotherapy].
    Pannuti F
    Minerva Chir; 1977 Oct; 32(19):1211-20. PubMed ID: 593576
    [No Abstract]   [Full Text] [Related]  

  • 22. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer.
    Namer M; Milano G; Khater R; Frenay M; Thyss A; Renée N
    Breast Cancer Res Treat; 1986; 8(2):161-3. PubMed ID: 2949788
    [No Abstract]   [Full Text] [Related]  

  • 25. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
    Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
    Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
    [No Abstract]   [Full Text] [Related]  

  • 26. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
    Castiglione M; Cavalli F
    Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].
    Wander HE; Kleeberg UR; Gärtner E; Hartlapp J; Scherpe A; Bönisch E; Nagel GA
    Onkologie; 1987 Apr; 10(2):104-6. PubMed ID: 2954006
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hormone treatment of metastasizing breast carcinoma].
    Navarra S; Melita P; Di Mauro S; Calbo L; Belnome N
    Minerva Chir; 1981 Jun; 36(12):853-60. PubMed ID: 6454856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medroxyprogesterone acetate (MPA) in the treatment of advanced breast cancer].
    Izuo M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2604-11. PubMed ID: 2956928
    [No Abstract]   [Full Text] [Related]  

  • 33. [Results of the treatment of patients with advanced breast with large doses of medroxyprogesterone acetate].
    Zulichowska J; Krawczyk J; Glińska H
    Pol Tyg Lek; 1988 May; 43(22):712-4. PubMed ID: 2976163
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].
    Amadori D; Ravaioli A; Barbanti F
    Minerva Med; 1977 Dec; 68(59):3967-80. PubMed ID: 74811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mitomycin C and high-dosage medroxyprogesterone acetate in the therapy of metastasizing breast cancer. Results of a phase II study of the Workshop for Internal Oncology of the German Cancer Association].
    Bartsch HH; Blossey HC; Nagel GA
    Onkologie; 1982 Oct; 5(5):249-57. PubMed ID: 6218456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Possible indications for medroxyprogesterone in the management of breast cancer].
    Bonte J
    Rev Med Suisse Romande; 1980 Sep; 100(9):781-5. PubMed ID: 7455478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The bioavailability of an orally administered medroxyprogesterone acetate suspension.
    Antal EJ; Gillespie WR; Albert KS
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):257-9. PubMed ID: 6222996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.
    Hortobagyi GN; Buzdar AU; Frye D; Yap HY; Hug V; Pinnamaneni K; Fraschini G; Halvorson HC; Blumenschein GR
    Breast Cancer Res Treat; 1985; 5(3):321-6. PubMed ID: 3161565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.